ArticleMolecular therapy. Nucleic acids2015
High-affinity RNA Aptamers Against the HIV-1 Protease Inhibit Both In Vitro Protease Activity and Late Events of Viral Replication.
Article in Molecular therapy. Nucleic acids, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Aptamers used for biosensors and targeted therapy.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2020Pooled it
- KSHV and cancer: understanding the oncogenic machinery for next-generation diagnostic tools and therapies.Archives of microbiology · 2026Review
- Single-stranded nucleic acid binding enhances the in vitro catalytic activity of Chikungunya virus nsP2 protease.BBA advances · 2026Article
- Generation of RNA aptamers against chikungunya virus E2 envelope protein.Journal of virology · 2025Article
- Development and characterization of high-affinity aptamers for HIV protease detection.Heliyon · 2024Article
- Aptamers targeting SARS-COV-2: a promising tool to fight against COVID-19.Trends in biotechnology · 2023Review
- Functional nucleic acids as potent therapeutics against SARS-CoV-2 infection.Cell reports. Physical science · 2023Review
- Aptamers in Virology-A Consolidated Review of the Most Recent Advancements in Diagnosis and Therapy.Pharmaceutics · 2021Review
- Aptamers for Anti-Viral Therapeutics and Diagnostics.International journal of molecular sciences · 2021Review
- Review
- Block-And-Lock: New Horizons for a Cure for HIV-1.Viruses · 2020Review
- Development of a novel, high-affinity ssDNA trypsin inhibitor.Journal of enzyme inhibition and medicinal chemistry · 2019Article
- Altered stoichiometry of an evolved RNA aptamer.RNA (New York, N.Y.) · 2018Article
- Aptamers in HIV research diagnosis and therapy.RNA biology · 2018Review
- Incorporation of aptamers in the terminal loop of shRNAs yields an effective and novel combinatorial targeting strategy.Nucleic acids research · 2018Article
- RNA Interference Therapies for an HIV-1 Functional Cure.Viruses · 2017Review
- Use of Aptamers as Diagnostics Tools and Antiviral Agents for Human Viruses.Pharmaceuticals (Basel, Switzerland) · 2016Review
- Post-ExSELEX stabilization of an unnatural-base DNA aptamer targeting VEGF165 toward pharmaceutical applications.Nucleic acids research · 2016Article
- A Highlight of Recent Advances in Aptamer Technology and Its Application.Molecules (Basel, Switzerland) · 2015Review
- Predicting the Uncertain Future of Aptamer-Based Diagnostics and Therapeutics.Molecules (Basel, Switzerland) · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
HIV-1 aspartyl protease (PR) plays a key role in virion morphogenesis, underscoring the effectiveness of protease inhibitors (PI). Despite their utility, side effects and drug-resistance remains a problem. We report the development of RNA aptamers as inhibitors of HIV-1 PR for potential use in anti-HIV gene therapy. Employing Systematic Evolution of Ligands by Exponential Enrichment (SELEX), we isolated four unique families of anti-HIV-1 PR RNA aptamers displaying moderate binding affinities (Kd = 92-140 nmol/l) and anti-PR inhibitory activity (Kis = 138-647 nmol/l). Second-generation RNA aptamers selected from partially randomized pools based on two of the aptamer sequences displayed striking enhancements in binding (Kds = 2-22 nmol/l) and inhibition (Kis = 31-49 nmol/l). The aptamers were specific in that they did not bind either the related HIV-2 protease, or the cellular aspartyl protease, Cathepsin D. Site-directed mutagenesis of a second-generation aptamer to probe the predicted secondary structure indicated that the stem-loops SL2 and SL3 and the stem P1 were essential for binding and that only the 3'-most 17 nucleotides were dispensable. Anti-PR aptamers inhibited HIV replication in vitro and the degree of inhibition was higher for second-generation aptamers with greater affinity and the inhibition was abrogated for a nonbinding aptamer variant.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.